Enhanced anticancer efficacy and tumor targeting through folate-PEG modified nanoliposome loaded with 5-fluorouracil

Van Minh Le¹², Trung Duc Tran Nho¹, Hai Trieu Ly², Thanh Sang Vo¹, Hoang Dung Nguyen¹³, Thi Thu Hue Phung¹, Aihua Zou³ and Jianwen Liu⁴

¹ NTT Hi-Tech Institute, Nguyen Tat Thanh University, 300A Nguyen Tat Thanh road, Ward 13, District 4, Ho Chi Minh City, Vietnam
² Research Center of Ginseng and Medicinal Materials (CGMM), National Institute of Medicinal Materials, Ho Chi Minh City 70000, Vietnam
³ Institute of Applied Chemistry, East China University of Science and Technology, 130 Meilong Road, Shanghai, People’s Republic of China
⁴ Department of Molecular and Cellular Pharmacology, Biomedical Nanotechnology Center, School of Pharmacy, East China University of Science and Technology, 130 Meilong Road, Shanghai, People’s Republic of China
⁵ Institute of Tropical Biology, Vietnam Academy of Science and Technology, Vietnam

E-mail: lvminh@ntt.edu.vn

Received 26 September 2016
Accepted for publication 20 December 2016
Published 3 February 2017

Abstract
Cancer targeted therapies have attracted considerable attention over the past year. Recently, 5-fluorouracil (5-FU), which has high toxicity to normal cells and short half-life associated with rapid metabolism, is one of the most commonly used therapies in the treatment of cancer. In this study the folic acid-conjugated pegylated nanoliposomes were synthesized and then loaded into them with 5-FU to improve the anti-tumor efficacy. The average size of liposomes (LPs) was about 52.7 nm which was identified by TEM. In the liposome uptake studies, the level uptake of folate-conjugated liposomes has increased compared to non-conjugated LPs according to LPs concentration, incubation time and presence of concentration of free folic acid (FA). The MTT assay and apoptotic test were carried out in HCT116 and MCF-7 cells for 24 or 48 h. The results revealed that the folate-PEG modified 5-Fu loaded nanoliposomes had strong cytotoxicity to cancer cell compared to pure 5-FU or PEG modified 5-FU loaded liposomes in a concentration- and time-dependent manner, and mainly enhanced the cancer cell death through folate-mediated endocytosis. Hence, the folate-PEG modified nanoliposome is a potential targeted drug-delivery system for the treatment of FR-positive cancers.

Keywords: targeted drug delivery, folate receptor, 5-flourouracil, nanoliposomes

Classification numbers: 2.05, 5.08, 5.09

1. Introduction
Chemotherapy is a general approach for cancer treatment. Until now 5-fluorouracil (5-FU) has been used clinically for colon cancer [1], breast cancer [2, 3], gastrointestinal cancers [4]. Unfortunately, serious toxic side effects and rapid degradation have limited its further clinical use [5, 6]. There are some researches about encapsulation of 5-FU in liposomal nanocarrier to improve biological half-life and/or reduce side effect [7, 8]. Liposomes are non-toxic and biocompatible. They can be incorporated both hydrophilic and hydrophobic drugs either in the aqueous phase or the lipid bilayer of the
2. Materials and methods

2.1. Materials

Hydrogenated soya phosphatidylcholine (HSPC) was obtained from Shanghai Taiwei Pharmaceutical Co. Ltd (China). Cholesterol (Chol) was ordered from Hubei prosperity Galaxy Chemical Co. Ltd (China). Monomethoxy-poly(ethylene glycol) (mPEG, MW = 2000, 99%), 5-fluorouracil (5-FU) and 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) were purchased from Sigma Chemical Company (St. Louis, MO, USA). Cholesteryl hemisuccinate (CHEM, Tokyo Chemical Industry Co. Ltd, Japan), rhodamine B (RhB, Acros Organics, USA) and folic acid (FA, Aladdin Chemical Reagent Co. Ltd, China) were obtained from commercial suppliers. All other reagents were of at least analytical grade and used without further purification.

Human breast adenocarcinoma cell line (MCF-7) and human colon cancer cell line (HCT116) were obtained from the Cell Bank of Type Culture Collection of Chinese Academy of Sciences (Cell Biology of Shanghai Institute, Shanghai, China). Roswell park memorial institute (RPMI) 1640 media; MCF-7 cells were cultured in DMEM. The culture medium was supplemented with 10% heat-inactivated fetal bovine serum.

2.2. Methods

2.2.1. Preparation of folate-modified PEG-liposomes. Liposomes were prepared by thin film hydration technique followed by high-pressure homogenization, previously described by Mourtas et al [22] and Chen et al [23]. In brief, the lipid mixture composed of CHEMS/NHS/TEA/PEG (PEG-CHEM or folate-PEG-CHEM, synthesized as reported by Wu et al [24]) were dissolved in a chloroform/methanol (2:1 v/v) mixture in a pear-shaped flask. The lipids were subsequently dried by rotary evaporation until a thin film was formed. Residual organic solvents were further dried under vacuum at room temperature overnight. The lipid film was hydrated with the appropriate volume of phosphate-buffered saline (PBS) buffer (pH 7.4), which contained 5-fluorouracil by sonication in a water bath. The drug was passively loaded. Non-encapsulated drug was removed by centrifugation at 16000 rpm for 30 min. FR-targeted liposome rhodamine B (F-RhB/PEG/LPs) and 5-FU-loaded folate-PEG modified nanoliposomes (F-5-FU/PEG/LPs) were prepared by the same method as previously reported [23, 24]. These liposome suspensions were passed through high-pressure homogenizer (HPH ATS Engineering, Canada) at 600 bar homogenization cycles. All the samples were lyophilized for long stability and frozen at −20 ºC for 12 h before being lyophilized for 48 h. The freeze-dried powders were rehydrated with double distilled water when required for further experiments.

2.2.2. Dynamic lights scattering and zeta potential measurements. The mean particle sizes, polydispersity index (PDI), and zeta potentials were measured by dynamic light scattering (DLS) using the Delsa™ Nano C Particle Analyzer (Beckman Coulter, USA) at a fixed angle of 165 ºC and 25 ºC. The mean diameter was calculated from the volume distribution curves given by the particle analyser.

2.2.3. Encapsulation efficiency and drug loading in liposomes. The concentration of 5-FU incorporated into liposome vesicles was monitored by centrifugation method. The samples were centrifuged at 16000 rpm for 30 min at 4 ºC. The ultrafiltrate contained the non-entrapped 5-FU was diluted with PBS and determined using a UV-Vis spectrophotometer (UV-1800, Shimadzu, Kyoto, Japan) at 265 nm. The drug content (DL) was calculated using the standard calibration curve and the percent of the drug encapsulation (EE) was calculated using the following formulas:

\[
DL(\%) = \frac{W_T - W_{UL}}{W_L} \times 100, \\
EE(\%) = \frac{W_T - W_{UL}}{W_T} \times 100,
\]

where \(W_T\) is the total amount of 5-FU added to the system, \(W_{UL}\) is the amount of the non-entrapped drug, and \(W_L\) is the total weight of liposomes.

2.2.4. Cell culture. The HCT116 cells were maintained in Roswell Park Memorial Institute (RPMI) 1640 media; MCF-7 cells were cultured in DMEM. The culture medium was supplemented with 10% heat-inactivated fetal bovine serum.
FBS (HyClone Laboratories Inc., Australia) and 1% penicillin/streptomycin. The cells are incubated in a humidified atmosphere of 5% CO₂ and 95% air at 37 °C.

2.2.5. Tumor targeted fluorescent liposomes uptake assay. Cells were seeded into 24-well plates and allowed to adhere 24 h in RPMI 2640 media with 10% serum. And then, the medium was removed and replaced by RPMI 1640 without serum. The cells were incubated with different concentrations of rhodamine encapsulated liposomes (F-Rh/PEG/LP or Rh/PEG/LP) for indicated time periods in the presence or absence of folate ligand at 37 °C. After that, cells were washed three times with cold PBS (pH 7.4, 4 °C) to remove unbound-Rh encapsulated liposomes and free FA. The cell finally were visualized and photographed under an inverted fluorescence microscope (Nikon Eclipse Ti-S, MA, USA).
2.2.6. In vitro cytotoxicity assay. The cells were plated at a density of $1 \times 10^4$ cells per well in 96-well plates and preincubated for 24 h. Then, the cells were treated to blank liposomes (FA/PEG/LP), 5-FU/LP, PEG/5-FU/LP, FA/PEG/5-FU/LP and pure 5-FU at different concentrations for 48 h, respectively. Cell viability was measured using the MTT method by Plate Reader (EnSpire® Multimode Plate Reader, Waltham, Massachusetts) at wavelengths of 492 and 630 nm. After exposure, the media were discarded. Then MTT solution with concentration of 1 mg ml$^{-1}$ was directly added into each well, and incubated for 4 h at 37 °C. The resulting formazan crystals were solubilized with 100 μl of dimethyl sulfoxide (DMSO). The absorbance was measured at 570 nm, with the absorbance at 630 nm as the background correction. The effect on cell proliferation was expressed as the percent cell viability. Untreated cells were taken as 100% viable.

2.2.7. Apoptosis determine. MCF-7 cells were plated into 96-well plates and allowed to adhere overnight at 37 °C in incubator. Cells were subsequently treated with 3 μg ml$^{-1}$ of different 5-FU liposome formulations for 24 h. Then, cells were washed three times with PBS (pH 7.4) and stained with Hoechst 33342 (5 μg ml$^{-1}$) for 10 min at room temperature. In the end of culture periods, culture cells were washed three times with pre-cold PBS to remove excess dye and cell morphology was captured by a fluorescence microscope.

2.2.8. Analysis. All data were performed triplicates in three individual experiments and expressed as mean ± SD. The student’s $t$-test analysis was performed to compare the means of two groups. The GraphPad Prism (GraphPad Software Inc., CA, USA) and excel (Microsoft) software were utilized to obtain graphs and statistics.

Figure 4. Effect of free FA on uptake of F-Rh/PEG/LP (a)–(d) and Rh/PEG/LP (e)–(h) at different FA concentrations of 0 μg ml$^{-1}$, 1 μg ml$^{-1}$, 10 μg ml$^{-1}$ and 200 μg ml$^{-1}$, respectively, in MCF-7 cells. The cells were incubated with rhodamine 123-loaded liposomes of 5 μg ml$^{-1}$ for 4 h and photographed using the reverse fluorescence microscopy.

Figure 5. The toxicity evaluation of folate-PEG modified nanoliposome by MTT methods. The cells MCF-7 (a) and HCT116 (b) were incubated with different concentrations of FA/PEG/LP for 24 or 48 h.
3. Results

3.1. Preparation and characterization of 5-FU liposomes

The PEGylated liposome and folate-modified liposome was prepared. Figure 1 shows the high-resolution transmission electron micrographs of the folate modified PEGylated liposomes. The 5-FU liposomes were found to have a spherical shape with one or two layer of lipid molecules. The mean diameter of 5-FU liposomes formulation was about 52.7 nm. The PDI is 0.181. The drug encapsulation efficiency and drug loading of FA/PEG/LP are 16.14% and 1.189%, respectively. Nano-size of drug-loaded liposomes have been prepared and modified with folate ligand to obtain tumor targeting.

3.2. Liposomes uptake by tumor cells in vitro

In order to understand the uptake mechanism of liposomes into cells via folate-mediated endocytosis, the cellular uptake study was evaluated in MCF-7 at different conditions. As show in figure 2, increasing the incubated concentration of Rh-loaded PEGylated liposomes (Rh/PEG/LP) resulted in an increase in the actual amount internalized. The internalization degree of folate-targeted Rh/PEG/LP (F-Rh/PEG/LP) is higher than that of Rh/PEG/LP (non-targeted liposome) after 2h of incubation in MCF-7 cells.

To investigate the effect of time on the folate-targeted liposomes, the FR-overexpressing cells, MCF-7, were incubated with non-targeted liposome (Rh/PEG/LP) and FR-targeted liposomes (F-Rh/PEG/LP) for 2h, 6h and 24h (figure 3). The F-Rh/PEG/LP showed distinctively increase of cell uptake degree compared to Rh/PEG/LP for various periods incubation with MCF-7 cells. The Rh/PEG/LP uptake just had a little change during incubations.

To represent the role of cell surface FRs in liposome binding, we were further performed free folate competition study. As showed in figure 4, the high folate concentration (200 µg ml⁻¹) significantly reduced the F-Rh-loaded liposome uptake in MCF-7 cells compared with low folate concentration (0, 1 and 10 µg ml⁻¹). But, there is no effect in reducing Rh/PEG/LP uptake.

Table 1. The IC₅₀ values of pure 5-FU and various formulation of 5-FU-loaded liposomes against MCF-7 or HCT116 cells for 24 and 48 h.

| Drugs             | MCF-7 cells (µg ml⁻¹) | HCT116 cells (µg ml⁻¹) |
|-------------------|-----------------------|------------------------|
|                   | 24 h  | 48 h  | 24 h  | 48 h  |
| 5-FU/LP           | 17.3  | 13.6  | >10   | 0.703 |
| 5-FU/PEG/LP       | 15.5  | 7.15  | 6.73  | 0.600 |
| F-5-FU/PEG/LP     | 10.2c,d| 4.47c,d| 4.07h,d| 0.527h,d|
| 5-FU              | >20   | 17.9  | >10   | 0.600 |

a, b, c, d p < 0.05, 0.01, 0.001, 0.05, respectively, compared to 5-FU/LP.

Figure 6. Cytotoxicity of different 5-FU-loaded nanoliposomes against HCT116 and MCF-7 cells after treatment for 24 or 48 h, respectively. MCF-7 cells treated with 5-FU-loaded nanoliposomes for 24 h (a) and 48 h (b). HCT116 cells treated with 5-FU-loaded nanoliposomes for 24 h (c) and 48 h (d). Data are presented as mean ± SD.
These experimental results indicated the folate-modified liposomes had a marked increase in cellular uptake compared to non-modified liposomes, and it was dependent on liposome concentration and incubated times. Furthermore, the uptake of folate-modified liposomes could be inhibited by the competition of high concentration of free FA. So, it suggested that the FA-modified liposome might be endocytosed via the FR in MCF-7 cell surface. In this study, we did not observed the saturation of the uptake capacity of the cells because of cell treatment with low concentration of liposomes.

3.3. Cytotoxicity study by MTT methods

Phospholipids are cell membrane component, so liposome made from lipid mixture (CHEMS/NHS/TEA/PEG) is well-known non-cytotoxicity [25]. As show in figure 5, there was no significant difference in cell viability over the liposome concentration range of 0 to 4 mg ml\(^{-1}\) for 24 h or 48 h in MCF-7 cells (figure 5(a)) and HCT116 cells (figure 5(b)). In addition, in the cellular uptake study, tumor cells have been showed significantly increased uptake to the folate-modified liposome. Therefore, any side effects in drug delivery process can be associated with the encapsulated drug alone and FA/PEG/LP, on the other hand, only acts as vehicles for drug. It suggests that FA/PEG/LP is a safe drug delivery system for biomedical applications.

The in vitro antitumor activity of 5-FU-loaded liposomes and pure drugs were determined by MTT assay. Two cancer cells, MCF-7 and HCT116, were treated with pure 5-FU, 5-FU/LP, 5-FU/PEG/LP and F-5-FU/PEG/LP at different drug concentrations in two different periods of time (24 h and 48 h). MTT results showed a significant reduction in the cell viability of the treatment for both 24 h and 48 h in MCF-7 and HCT116 cell lines (figure 6). Here, the drug-loaded liposomes had similar activity to pure 5-FU in inhibiting the growth of HCT116 or MCF-7 cells.

The half maximal inhibitory concentration (IC\(_{50}\)) values of pure 5-FU, 5-FU/LP, 5-FU/PEG/LP and F-5-FU/PEG/LP against tumor cells were showed in table 1. There is little difference between pure 5-FU and other 5-FU-liposome formulations in HCT116 cell for 24 h or 48 h incubation, respectively (figures 6(c) and (d)). However, 5-FU-liposome formulations showed stronger cytotoxicity compare pure 5-FU in MCF-7 cells (figures 6(a) and (b), and table 1). Furthermore, F-5-FU/PEG/LP exhibited greater cytotoxic activities to pure 5-FU or 5-FU/PEG/LP in MCF-7 cells. In addition, the MTT results also showed that 5-FU loaded-liposome formulations inhibited tumor cell growth in a time-dependent manner from 24 h to 48 h. This revealed that folate moieties in F-5-FU/PEG/LP would be conducive to enhancing a cytotoxic effect by binding of the liposomes on MCF-7 cells and subsequently increasing their intracellular uptake via FR-mediated endocytosis and accumulating in tumor cells.

3.4. Apoptotic analysis

Tumor cell general underwent apoptosis in response to anti-cancer agents. To elucidate drug-loaded liposomes induced apoptosis in MCF-7 cells, cell nuclei was stained by Hoechst 33342 dye and imaged by fluorescence microscope. (A) Control, (B) blank LPs, (C) pure 5-FU, (D) 5-FU/LPs, (E) 5-FU/PEG/LPs and (F) F-5-FU/PEG/LPs.

Figure 7. Tumor cell apoptosis assay. The MCF-7 cells were treated with different drug-loaded formulations containing 5-FU concentration of 3 \(\mu\)g ml\(^{-1}\) for 24 h. The nuclear morphologies of apoptotic cells were stained with Hoechst 33342 dye and imaged by fluorescence microscope. (A) Control, (B) blank LPs, (C) pure 5-FU, (D) 5-FU/LPs, (E) 5-FU/PEG/LPs and (F) F-5-FU/PEG/LPs.
4. Conclusion

Some biocompatible polymers such as poly(lactide)-tocopheryl polyethylene glycol, chitosan and PEG, have been widely used for the tumor-targeted delivery and site-specifically release of of anticancer drugs (paclitaxel, curcumin and doxorubicin) [26–28]. In recent years, the use of liposomes to increase the therapeutic index of chemotherapeutic drugs and to offer drug targeting and controlled release has emerged as a promising strategy against cancer [8, 29, 30]. PEGylated phospholipids are commonly used to protect the liposome surface from penetration and disintegration by plasma proteins or to avoid monocyte/macrophage uptake. PEGylated phospholipids mainly accumulate at tumor sites [27, 33]. Additionally, the liposome with FA modification can provide active targeting capability to FR-positive cancer. The MTT assay showed that the blank liposomes had no significant toxic effect on the growth of two tumor cell lines (HCT116 and MCF-7). Further, the testing of cytotoxicity and apoptosis of 5-FU-loaded liposomes indicated that folate-modified liposomes effectively enhanced anticancer activity of drug through folate-mediated endocytosis. The F-5-FU/PEG/LP was found to have significantly greater cancer-inhibitory effect than without folate conjugation or pure 5-FU. Therefore, the results of this study illustrated this drug delivery system could be beneficial in the cancer treatment by targeting 5-FU to the tumor cells and reducing its toxicities. Moreover, further studies are in progress to improve drug loading of this system.

Acknowledgment

This research is funded by NTTU Foundation for Science and Technology Development under grant number 2016.01.30. The authors would like thanks to Dr YiYin Chen for carrying out the liposome synthesis and the TEM experiments.

References

[1] Arkenau H T, Bermann A, Rettig R, Strohmeyer R and Porschen R 2003 Ann. Oncol. 14 395
[2] Karapetis C S, Patterson W K, Pittman K B, Kotasek D and Sage R E 1999 Aust. N. Z. J. Med. 29 517
[3] Cameron D A, Gabra H and Leonard R C 1994 Br. J. Cancer 70 120
[4] Leichman C G 1994 Cancer Invest. 12 166
[5] Malet-Martino M and Martino R 2002 Oncologist 7 288
[6] Smith I E et al 2004 Ann. Oncol. 15 751
[7] Milla P, Dosio F and Catell L 2012 Curr. Drug Metab. 13 105
[8] Nalwa H S and Webster T J E 2007 Cancer Nanotechnology (Los Angeles, CA: American Scientific Publishers)
[9] Schwendener R A and Schott H 2010 Methods Mol. Biol. 605 129
[10] Çağdaş M, Sezer A D and Bucaş S 2014 Liposomes as potential drug carrier systems for drug delivery Application of Nanotechnology in Drug Delivery ed Ali Demir Sezer (Croatia: Intech) pp 1–100
[11] Allen T M and Cullis P R 2004 Science 303 1818
[12] Chang H-I and Cheng M-Y 2012 J. Nanomed. Biother. Discovery 1 195
[13] Wang Y, Li P, Chen L, Gao W, Zeng F and Kong L X 2014 Drug Deliv. 22 191
[14] Zwicke G L, Mansoori G A and Jeffery C J 2012 Nano Res. 3 18496
[15] Qin X C, Guo Z Y, Liu Z M, Zhang W, Wan M M and Yang B W 2013 J. Photochem. Photobiol. B 120 156
[16] Ai J, Xu Y, Li D, Liu Z and Wang E 2012 Talanta 101 32
[17] Pan X and Lee R J 2004 Expert Opin. Drug Deliv. 1 7
[18] Sudimack J and Lee R J 2000 Adv. Drug Deliv. Rev. 41 147
[19] Duan J, Liu M, Zhang Y, Zhao J, Pan Y and Yang X 2012 J. Nanopart. Res. 14 761
[20] Kalli K R et al 2008 Gynecol. Oncol. 108 619
[21] Parker N, Turk M J, Westrick E, Lewis J D, Low P S and Leamon C P 2005 Anal. Chem. 77 284
[22] Mourtas S et al 2011 Colloid Surf. B 84 214
[23] Chen Y et al 2016 Colloid Surf. B 140 74
[24] Wu J, Liu Q and Lee R J 2006 Int. J. Pharm. 316 148
[25] Mallick S and Choi J S 2014 J. Nanosci. Nanotechnol. 14 755
[26] Nguyen H N et al 2016 Adv. Nat. Sci. 7 025001
[27] Ha P T et al 2016 Adv. Nat. Sci. 7 015001
[28] Nguyen K T, Le D V, Do D H and Le Q H 2016 Adv. Nat. Sci. 7 025018
[29] Singh R and Nalwa H S 2011 J. Biomed. Nanotechnol. 7 489
[30] Nalwa H S 2014 J. Biomed. Nanotechnol. 10 1635
[31] Gubernator J 2011 Expert Opin. Drug Deliv. 8 565
[32] Xing H, Hwang K and Lu Y 2016 Theranostics 6 1336
[33] Nie S, Xing Y, Kim G J and Simons J 2007 Ann. Rev. Biomed. Eng. 9 257